Product Description
The research-grade biosimilar is a recombinant humanized IgG2/4 kappa monoclonal antibody that inhibits the cleavage of C5 into C5a and C5b by C5 convertases. Inhibition of C5 cleavage prevents the generation of the terminal complement complex C5b-9. Both C5a and C5b-9 have proinflammatory and prothrombic properties and play a significant role in complement-mediated diseases such as paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS). The original monoclonal antibody received FDA approval for the treatment of PNH and aHUS. This monoclonal antibody also received approval to treat adults suffering from general Myasthenia Gravis (gMG) but are anti-AChR antibody-positive.
Biovision | A2138 | Anti-C5 (Eculizumab), Humanized Antibody DataSheet
Antibody Target: Complement C5
Target Alternative Name: C5D, C5a, C5b, ECLZB, CPAMD4, C5, Complement C5
Tag Line: A humanized monoclonal antibody that targets complement protein C5 and prevents activation of the terminal complement complex C5b-9 which has a central role in disorders such as paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic syndrome (aHUS), and Myasthenia Gravis (gMG)
Category: Biosimilars
Host: Recombinant
Isotype: IgG2/4, kappa
Species Reactivities: Human
Immunogen Sequence: Eculizumab
Accession #: DB01257
Gene ID:
Appearance: Colorless liquid
Form: Liquid
Concentration: Lot specific
Formulation: In PBS, pH 7.5
Purification: Protein A purified
Application:
Positive Control:
Application And Usages:
Country of Animal Origin: USA
Country of Manufacture: USA
Usage: For Research Use Only! Not to be used in humans.
Handling: The antibody solution should be gently mixed before use.
Western Blot Verified: FALSE
Immunocytochemistry Verified: FALSE
Immunofluorescence Verified: FALSE
Immunoprecipitation Verified: FALSE
FACS Verified: FALSE
ELISA Verified: FALSE
ChIP Verified: FALSE
Dot Blot Verified: FALSE
Flow Cytometry Verified: FALSE